An investigational treatment option when other treatments fail.

If you are suffering from a myelodysplastic syndrome (MDS) and have unsuccessfully been treated with Vidaza® (azacitidine) or Dacogen® (decitabine), you may want to consider speaking with your physician.

ONTIME is a phase III investigational trial for patients with MDS that have not responded to previous treatment, become intolerant to, or progressed after azacitidine (Vidaza®) or decitabine (Dacogen®). In this clinical trial, patients will be randomly assigned to one of two regimens; treatment with rigosertib plus best supportive care or best supportive care in the absence of rigosertib. Rigosertib is an investigational agent being evaluated for MDS, other blood malignancies and solid tumors. Patients in both the rigosertib arm and the best supportive care arm will be monitored closely throughout the trial and hospital stays are not necessary.

The ONTIME trial is supported by an investigational research award and outreach and education from The Leukemia & Lymphoma Society®. The MDS Foundation is also working to support the ONTIME trial through outreach and education. The ONTIME trial has received a Special Protocol Assessment (SPA) from the United States Food & Drug Administration (FDA).

• Visit the MDS Foundation patient information link,
  www.mds-foundation.org/patient-handbooks to learn more about myelodysplastic syndromes.
• The Leukemia & Lymphoma Society’s (LLS’s) Information Specialists can assist MDS patients navigate through treatment, financial and social challenges and give accurate, up-to-date disease and treatment information. To reach an Information Specialist, please click the link below: www.lls.org/#/diseaseinformation/getinformationsupport/informationspecialists/

Learn more about the ONTIME clinical trial:

• Call the ONTIME Trial Helpline (855) 609-6564 toll free
• Visit http://www.clinicaltrials.gov/ct2/show/NCT01241500